Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians.
about
Acute sterile endophthalmitis following intravitreal bevacizumab: case series.Ranibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema.Topical application of PPADS inhibits complement activation and choroidal neovascularization in a model of age-related macular degeneration.One-Year Feasibility Study of Replenish MicroPump for Intravitreal Drug Delivery: A Pilot Study.Topical application of a G-Quartet aptamer targeting nucleolin attenuates choroidal neovascularization in a model of age-related macular degeneration.Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59IgG Fab fragments forming bivalent complexes by a conformational mechanism that is reversible by osmolytes.Digital reader vs print media: the role of digital technology in reading accuracy in age-related macular degenerationDifferential regulation of angiogenesis using degradable VEGF-binding microspheres.Ranibizumab in diabetic macular edemaTGF-β participates choroid neovascularization through Smad2/3-VEGF/TNF-α signaling in mice with Laser-induced wet age-related macular degeneration.VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration.A2E-associated cell death and inflammation in retinal pigmented epithelial cells from human induced pluripotent stem cells.Cytosolic expression of functional Fab fragments in Escherichia coli using a novel combination of dual SUMO expression cassette and EnBase® cultivation mode.Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.Photokinetic Drug Delivery: Near infrared (NIR) Induced Permeation Enhancement of Bevacizumab, Ranibizumab and Aflibercept through Human Sclera.
P2860
Q34182273-7BC4C232-0C37-48A9-B78E-7E12BD0D8D68Q34711043-3327120F-E1BE-4A6A-8032-AEBC3EAEE090Q35018565-44F368D4-2FAB-4A89-A9FC-C463BD048A73Q35167647-442EB970-B35A-474C-9D65-96DC98B5E6E6Q35774515-92066FDA-1429-482C-9FE7-B6E86AC0EC50Q36380744-5A578710-DACD-461C-89C7-D6D7C8C147CAQ36466773-FE7A9690-45AC-44C5-A443-8F4F57F7C22DQ36832272-0BD1088F-FF22-405F-A44C-496796A8FAB5Q36899777-4635A232-8074-49A0-B0B8-97FDDFA99D78Q37417759-4451011C-C9E6-46D2-AD09-94A2C23446ADQ41550102-D68E5C1A-AC25-43A8-BB76-456B8277973AQ44857733-6C3F7C19-824D-46C6-8FA7-246F5C574966Q50091811-D984A005-CCDA-4E01-B8BF-B1035174A310Q50646372-1A609249-B5B0-41FD-90C7-F030572568E7Q53373714-B25950EE-43CF-4B74-9190-23D7243EDA47Q55353695-4ED7C0C5-CDDB-4795-AFBC-8B06D005414D
P2860
Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians.
@en
Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians.
@nl
type
label
Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians.
@en
Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians.
@nl
prefLabel
Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians.
@en
Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians.
@nl
P2860
P356
P1476
Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians.
@en
P2093
Pearse A Keane
Srinivas R Sadda
P2860
P304
P356
10.1155/2012/483034
P577
2011-12-18T00:00:00Z